Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

ABSTRACT: Personalized treatment is an attractive strategy that promises increased efficacy with reduced side effects in cancer. The feasibility of such an approach has been greatly boosted by next-generation sequencing (NGS) techniques, which can return detailed information on the genome and on the transcriptome of each patient's tumor, thus highlighting biomarkers of response or druggable targets that may differ from case to case. However, while the number of cancers sequenced is growing exponentially, much fewer cases are amenable to a molecularly-guided treatment outside of clinical trials to date. In multiple myeloma, genomic analysis shows a variety of gene mutations, aneuploidies, segmental copy-number changes, translocations that are extremely heterogeneous, and more numerous than other hema

SUBMITTER: Bolli N 

PROVIDER: S-EPMC7057289 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature